Pure Global AI
NCT06326736Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

An Exploratory Clinical Study of Safety and Efficacy of Neoantigen mRNA Vaccines in the Treatment of Patients With Resectable Pancreatic Cancer
Jinling Hospital, ChinaPhase 1ClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Surgery
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Jinling Hospital, China
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Dec 01, 2026
Enrollment
12 participants
Primary outcome

Incidence of Treatment Emergent Adverse Events (TEAEs)

Summary

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic
 cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized
 cancer mRNA vaccines.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06326736
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06326736 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jinling Hospital, China and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.